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ABSTRACT: We tested the targeting efficiency of magnetoliposomes (MLPs)
labeled with tripeptide arginine-glycine-aspartic acid (RGD) on two types of cells:
HeLa cells expressing RGD receptors and 3T3 cells lacking RGD receptors. The
targeting ability of RGD-MLPs was compared to that of bare MLPs and MLPs
stabilized with poly(ethylene glycol) (PEG). Cellular internalization of these
liposomes was determined by flow cytometry and confocal microscopy, which
showed that both types of cells took up more nontargeting MLPs than targeting
RGD-MLPs or PEG-MLPs, with PEG-MLPs showing the lowest degree of
internalization. The presence of specific receptors on HeLa cells did not facilitate
the binding of RGD-MLPs, probably due to the presence of PEG chains on the
liposomal surface. The polymer increases the circulation time of the liposomes in the
organism but reduces their interactions with cells. Despite the localization of the
RGD peptide on the tip of PEG in RGD-MLPs, the interaction between the liposome
and cell was still limited. To avoid this drawback, targeting drug delivery systems can
be prepared with two types of PEG: one of a short length to enable biocompatibility and the other of a longer chain to carry the
ligand.
■ INTRODUCTION
The conventional administration of drugs presents some
limitations and problems. For many treatments, large drug
doses are required to achieve high local concentrations, with the
potential risk of adverse side effects. Moreover, the lack of
targeted delivery to the site of interest and the rapid clearance by
the mononuclear phagocyte system (MPS) pose other critical
challenges for the administration of any drug.1 Recent advances
in materials science and biotechnology have enabled the
development of new methods of drug delivery that can
potentially overcome the abovementioned limitations. One of
these methods involves the use of particulate systems for drug
delivery, such as microspheres, nanoparticles, lipoproteins,
soluble polymers, micelles, and liposomes.2 Targeting nano-
particles can increase the efficiency of drugs by delivering them
directly to the sites of interest. This requires site-directed ligands
on the surfaces of the systems to further enhance their selective
targeting or the engineering of stimuli-sensitive systems that
change their physical properties in response to an external
stimulus (e.g., temperature, pH, ionic strength, or a magnetic
gradient for magnetic targeting).3
Magnetic nanoparticles (MNPs) are promising stimuli-
sensitive drug carriers because of their responsiveness to a
magnetic field. An applied extracorporeal magnetic field can
concentrate these nanosystems at the desired site, keeping them
in a particular place for a given period of time until the
encapsulated drug is released, therebyminimizing any side effects
due to nonspecific distributions.4−6
Ligands (e.g., antibodies, peptides, or carbohydrates)
recognizing tumor-associated antigens expressed on tumor cell
surfaces have been used for cancer therapy. Some of the
structures suitable for tumor targeting belong to integrins, a
family of heterodimeric cell surface receptors, consisting of α-
and β-subunits, which mediate cell adhesion to the extracellular
matrix and other cells.7 These cell surface receptors are
universally expressed by tumor and normal cells. However, the
αV (especially αVβ3) forms are highly expressed on endothelial
cells lining tumor cells but poorly expressed on resting
endothelial cells and most normal organs, making them a
potential target for antiangiogenesis treatment. Targeting the
αVβ3 integrin may provide an opportunity to targeting the tumor
endothelium and destroy tumor vessels without harming the
microvessels of normal tissue.8 Indeed, targeting tumor
vasculature rather than the tumor cells themselves has been
described as a promising new approach for cancer therapy.9 The
ligands that have been used for targeting these integrins carry the
arginine-glycine-aspartic acid (RGD) motif. The RGD sequence
forms the basis of a variety of RGD-containing peptides that
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display preferential binding to either the αVβ3 integrin and
related αV integrins or other types of integrins. Because the RGD
sequence is conserved in all natural and newly developed ligands,
the relative affinity and specificity of the peptides and proteins are
determined by other amino acid residues flanking the RGD
motif, especially the two amino acids following the aspartic
acid.10 In addition to the direct interactions between these
residues and integrin, flanking groups influence the folding of the
peptide and thus its conformation. Cyclization is commonly used
to improve the binding properties of RGD peptides.11 Linear
RGDpeptides are highly susceptible to chemical degradation due
to the reaction of the aspartic residue with the peptide
backbone.12 Because the rigidity conferred by cyclization
prevents this problem, cyclic peptides are more stable and
suitable for biological targeting. Thus, RGD-containing peptides
have been used in tumor imaging, treatments against angio-
genesis, and tumor targeting with radionuclides or chemo-
therapeutic drugs.13
Liposomes have been extensively investigated as potential
drug carriers in cancer chemotherapy.14 A major drawback of
using liposomes is their rapid degradation by the mononuclear
phagocyte system (MPS). As with all foreign colloidal particles,
liposomes are quickly recognized as “nonself” and taken up by
the cells of the MPS, chiefly macrophages in the liver and spleen.
To prolong their circulation time in vivo, poly(ethylene glycol)
(PEG) is grafted onto the lipid surface.15 Such liposomes,
Figure 1. Characterization of iron oxide nanoparticles: (A) TEM images; (B) HRTEM image and fast Fourier transform (FFT) from the highlighted
region; and (C) HAADF image of the sample. The right panel is the crystal model of magnetite seen along the [110] zone axis, which matches with the
highlighted region of the image.
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classified as sterically stable liposomes, present a hydrophilic
corona around the particles that minimizes nonspecific
adsorption of proteins onto the liposome surface, thus rendering
the liposomes “invisible” to macrophages (“stealth” effect).
Liposomes smaller than 200 nm can exploit a feature of the
tumor microenvironment, the so-called enhanced permeability
and retention (EPR) effect.16 Because of the leaky vasculature of
the tumor, the intratumoral accumulation of liposomes is high
relative to normal tissue.17,18
In this study, magnetoliposomes (MLPs) and sterically
stabilized liposomes containing magnetic nanoparticles (PEG-
MLPs) were prepared. Such liposomes can be targeted to the site
of interest by applying an external magnetic field. To generate
RGD-MLPs, the RGD peptide was grafted onto the distal end of
the PEG chain attached to the liposomes to target integrin αVβ3
expressed on many cancer cells. Hence, this kind of liposome
(RGD-MLPs) combines magnetic and receptor-specific target-
ing. The targeting efficiency of RGD-MLPs in vitro was tested on
two types of cells: 3T3 murine Swiss albino embryo fibroblasts
andHeLa cells derived from human epithelial cervical cancer. We
selected these cell lines from different species and with different
embryonic origins as model systems to understand the cell-
specific responses induced by our nanoparticles.19
Cellular uptake of RGD-MLPs, MLPs, and PEG-MLPs was
studied in 3T3 and HeLa cells after establishing the safe working
concentrations of these liposomes for cell labeling. To visualize
the cellular uptake of the liposomes by confocal microscopy and
flow cytometry, liposomes were prepared by incorporating 0.3
mol % rhodamine B (Rho) into the lipid bilayer.
Figure 2. (A) Effect of an external magnet on the ferrofluid. (Photograph courtesy of J. Estelrich Copyright 2016) (B) Magnetization measurement at
298 K of a sample of lyophilized ferrofluid.
Figure 3. Characterization of magnetoliposomes (MLPs): (A) schematic diagram of the structure of a RGD-MLP; (B) hydrodynamic diameter
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■ RESULTS
Characterization of MNPs and RGD-MLPs. MNPs were
synthesized by coprecipitating iron salts in the presence of PEG.
The resulting ferrofluid was characterized by transmission
electron microscopy (TEM), high-resolution TEM (HRTEM),
high-angle annular dark-field imaging (HAADF), (Figure 1)
photon correlation spectroscopy (PCS), and Doppler micro-
electrophoresis.
From the TEM images, we can observe that the ferrofluid
consisted of small clusters of primary particles with diameters
between 5 and 15 nm (Figure 1A). Figure 1B displays a HRTEM
image of the iron oxide nanoparticle sample. The appearance was
that of ultrafine agglomerate crystallites. The two distinct levels
of contrast indicate that nanoparticles contained several
components. The FFT of the labeled squared region showed
the diffraction pattern of magnetite in the [112] zone axis. The
HAADF image (Figure 1C) showed the nanoparticles at atomic
resolution. The right panel is the crystal model seen along the
[110] zone axis, which matched with the highlighted region of
the image. PEG-coated magnetic nanoparticles had an intensity-
weighted average hydrodynamic diameter of 62 ± 13 nm with a
polydispersity index (PI) of 0.10 ± 0.06 from PCS measure-
ments. The hydroxyl groups of the PEG were responsible for the
low surface charge of the nanoparticles at pH 6.5 (ζ-potential∼5
mV). The particles responded to an external magnetic field
(Figure 2A), exhibited superparamagnetic behavior, and had a
magnetization of 55 emu g−1 at 5 kOe at room temperature
(Figure 2B). The colloidal stability of the ferrofluid under
perikinetic conditions was extremely high; the size and size
distribution remained unaltered for more than 5 years. This
ferrofluid was encapsulated in bare and PEGylated liposomes.
One part of the PEGylated liposomes was functionalized with the
RGD peptide at a ratio of 1:10 RGD/PEG. For flow cytometry
and confocal microscopy, fluorescence probe Rho was inserted
into MLPs at a ratio of 100:3 lipid/Rho.
Figure 3 shows the main characteristics of these MLPs. Figure
3A is a schematic representation of the functionalizedMLPs. The
average hydrodynamic diameter was 220 ± 4 nm for MNPs, 146
± 4 nm for PEG-MNPs, and 161 ± 0.5 nm for RGD-MNPs
(Figure 3B). The size distribution of all of the MLPs was
monomodal (PI ∼ 0.20). Electrophoretic mobility measure-
ments of MLPs, PEG-MLPs, and RGD-MLPs indicated ζ-
potentials of −4.2 ± 0.1, −10.3 ± 0.3, and −13.5 ± 0.1 mV,
respectively (mean ± standard deviation) (Figure 3C). The iron
content, determined spectroscopically, was 10 mM. This
amount, in relation to the phospholipid concentration of 25
mM, corresponded to 23.52 mg of iron by millimole of
phospholipid.
The lipids present in the liposome membrane have the
following molecular surface areas: 0.62 nm2 for dimyristoyl
phosphatidyl choline (DMPC),20 0.48 nm2 for distearoyl
phosphatidyl ethanolamine (DSPE),21 and 0.35 nm2 for
cholesterol (CHOL).22 From the molar ratio of RGD-MLPs
and taking into consideration a symmetrical distribution of lipids
in the bilayer and ideal mixing, where the area per molecule is
simply a weighted average of the pure component areas, an
average lipid molecular surface area of 0.514 nm2 was calculated.
Figure 4. Flow cytometry histograms of 3T3 cells incubated for 4 h with MLPs, PEG-MLPs, or RGD-MLPs and their nonmagnetic counterparts. In the
center, the fluorescence of untreated cells is shown.
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Assuming a liposome diameter of 100 nm and that all of the RGD
motifs present were coupled to a maleimide group (this reaction
has been reported to be one of the most efficient reactions in
bioconjugate chemistry),23 the number of RGD molecules
present in the outer monolayer of the liposomes was ∼180. The
average number of iron oxide cores in the liposomes was
calculated to be 1.35, which is consistent with the inner volume of
a liposome as well as the hydrodynamic radius of a magnetic
particle. For this calculation, the iron oxide cores were assumed
to be monodispersed (12 nm in diameter), perfectly spherical,
and with a density of 5100 kg m−3.
Cell Viability. Before studying the cellular internalization of
MLPs, safe working concentrations of the three types of MLPs
were first established. The effects of targeting RGD-MLPs on
HeLa and 3T3 cells were evaluated and compared to those of
nontargeting MLPs and PEG-MLPs. First, the cytotoxic effects
exerted by the ferrofluid and bare liposomes were determined. It
is known that iron oxide nanoparticles can be internalized into
cellular compartments, such as the lysosome, and that
permeabilization of the lysosome membrane promotes cell
death.24 We observed that after 24 h of incubation the ferrofluid
did not affect the cell cycle in the range of 0.05−12 mM Fe, as
determined by the neutral red (NR) uptake assay.
The half-maximal inhibitory concentration (IC50) of the
ferrofluid in both cell types was >12 mM (Table S1 and Figure
S1). The range of safe concentrations was lower in the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. In the 0.05−0.20 mM range, the iron oxide cores
themselves did not exert toxic effects on the cells. IC50 values
of 5.6 and 8.4 mM were obtained in 3T3 and HeLa cells,
respectively. To determine any potential toxic effects of the
liposomes, cell viability was assessed in the presence of bare
liposomes, that is, liposomes formed solely of DMPC and CHOL
at the same molar ratio as that used to prepare the three types of
MLPs studied here. This lipid composition was completely
innocuous (IC50 > 20 mM) (Table S1 and Figure S2). To study
the toxicity of the three types of MLPs, cells were exposed to a
concentration range of nanoparticles (0.08−20 mM) for 24 h.
These nanoparticles induced some toxicity at relatively high
concentrations, especially those containing PEG (Table S1 and
Figures S3−S5). On the basis of these results, subsequent
experiments were performed using a phospholipid concentration
of 0.60 mM (with an iron content of 0.2 mM).
Flow Cytometry. Flow cytometry was used to determine the
relative amount of intracellular uptake of the different MLPs.
Forward and sideward scatter diagrams of single-cell suspensions
demonstrated that at least the majority of cells were still intact,
with only small amounts of debris occurring (Figures S6 and S7).
To distinguish between fluorescence caused byMLP binding and
autofluorescence from unlabeled cells, the autofluorescence of
cells was measured and a cutoff point was determined. After
incubation of 3T3 and HeLa cells with MLPs, PEG-MLPs, or
RGD-MLPs for 4 h, flow cytometry revealed significantly higher
mean fluorescence intensities for cells incubated with MLPs
(regardless of their composition) compared to those for control
cells (Figures 4 and 5). Both endpoints emphasize different
properties of the cell. Whereas MTTmeasures the mitochondrial
activity, NR gives information about the membrane integrity. In
Figure 5. Flow cytometry histograms of Hela cells incubated for 4 h with MLPs, PEG-MLPs, or RGD-MLPs and their nonmagnetic counterparts. In the
center, the fluorescence of untreated cells is shown.
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addition, NR has to be accumulated in lysosomes for staining and
changes in lysosomal function/pH can cause decreased dye
uptake. Therefore, uptake of particles, for instance, could cause
the changes in lysosome pH. However, only in the case of
ferrofluid (see Figure S1), a strong influence of the endpoint
method on the selectivity on the mode of action was observed.
Changes in cell viability determined by these two endpoints
suggested that the interaction of ferrofluid with cells involves a
poor interaction with the plasmatic membrane. The bare and
PEGylated MLPs (Figure S3) did not demonstrate so strong
differences between these systems. In both cases, the decrease in
cell viability usingMTT suggested the uptake and internalization
mediated by the nanoparticulated system.
In 3T3 cells, MLP uptake increased the mean fluorescence
intensity by a factor of 6−7, whereas RGD-MLPs and PEG-
MLPs produced a fluorescence signal 6 and 4 times stronger,
respectively. The differences in fluorescence intensities between
MLPs and the other two liposomes were greater in HeLa than in
3T3 cells. In this way, MLPs increased the mean fluorescence
intensity by a factor of 8−9 in HeLa cells, with the fluorescence
intensity being only 5 times stronger with RGD-MLPs and 4
times stronger with PEG-MLPs. To ascertain whether the
magnetic properties of the liposomes affected cellular uptake, the
uptake of bare liposomes with no ferrofluid was also studied. In
3T3 and especially HeLa cells, MLPs were internalized to a
higher extent than in bare liposomes. Table 1 summarizes the
results.
Confocal Microscopy. To visualize the distribution of the
fluorescence signals in cells, laser scanning confocal microscopy
was performed with 3T3 and HeLa cells (Figures 6−9) after 2, 4,
and 24 h of incubation with any of the types of MLP bearing Rho
(red channel). The cell membrane was stained with cell-
membrane-impermeable dye Alexa Fluor 488-conjugated wheat
germ agglutinin (WGA) (green channel), whereas the nucleus
was stained with membrane-permeable dye Hoechst 33342 (blue
channel). Figure 6 shows the negative control of both 3T3 and
HeLa cells.
Figures 7 and 8 show representative confocal images of the
cells incubated for 2, 4, or 24 h with bare MLPs (Figure 7) or
RGD-MLPs (Figure 8). Figure 9 shows the representative
confocal images of the cells incubated with PEG-MLPs. Images
obtained from the red and green channels were merged. After
internalization, nanoparticles are initially confined inside endo-
somes, which are submicrometric vesicles of the endocytic
pathway. Internalization of nanoparticles into endosomes is
indicated by the red liposome fluorescence between the green
cell membrane and the blue nucleus in the confocal images,
which is absent in the images of corresponding control cells.
Figure 7A shows that MLP internalization in 3T3 cells after 24 h
of incubation is greater. In HeLa cells (Figure 7B), MLP
internalization could already be observed at 2 h but became lower
at 24 h. Thus, the kinetics of nanoparticle uptake depended on
the type of cell and it is particularly fast. RGD-MLP
internalization could be clearly seen in 3T3 cells at 2 and 4 h
of incubation, but only a few cells displayed uptake after 24 h
(Figure 8A). By contrast, HeLa cells did not internalize RGD-
MLPs at any of the time points studied (Figure 8B). The
internalization of PEG-MLPs was unappreciable at any
incubation time (Figure 9A,B). These results were consistent
with those obtained with flow cytometry.
■ DISCUSSION
Adding specific ligands to the surfaces of nanoparticles to target
receptors that are overexpressed in anomalous circumstances in
cells (e.g., the overexpression of αVβ3 integrin or CD44 in
cancerous cells) is a good strategy for concentrating nano-
particles at the sites of interest and, thus, facilitating their
internalization and accumulation inside the desired cells via the
EPR effect. Moreover, nanoparticles can carry a drug and release
it more efficiently inside the cells of interest. Nanoparticles can
Table 1. Fluorescence (Mean and Increase) Observed for
Cells Incubated with MLPs with Respect to Control Cells
cell line
Hela 3T3
liposome type F/Fo mean F/Fo mean
MLP 8.46 1339 6.43 818
PEG-MLP 4.06 866 4.17 511
RGD-MLP 5.26 1327 6.13 904
bare liposome 3.83 3231 4.13 1272
PEG-liposome 2.48 1407 2.70 843
RGD-liposome 3.83 1829 4.54 1235
control 1.00 331 1.00 186
Figure 6. Confocal microscopy images of the cells incubated without nanoparticles for 4 h. Green fluorescent signals indicate the cellular membranes,
and the blue ones, the nucleus.
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also contain iron oxide cores conferring superparamagnetic
properties of a suitable size. Such nanoparticles can be used to
induce death of the cells in the vicinity by generating heat after
exposure to radiofrequency radiation (hyperthermia) or to
visualize pathological conditions by magnetic resonance imaging.
In conclusion, it is possible to prepare nanoparticulate systems
that behave as multifunctional nanoplatforms. Among the
different types of nanoparticles that can be used as theranostic
Figure 7.Confocal microscopy images of the intracellular distribution of MLPs after three times of incubation (2, 4, and 24 h). Green fluorescent signals
indicate the cellular membranes, blue signals, the nucleus, and red signals, the nanoparticles: (A) 3T3 cells and (B) HeLa cells.
Figure 8.Confocal microscopy analysis of the intracellular distribution of RGD-MLPs after three times of incubation (2, 4, and 24 h). Green fluorescent
signals indicate the cellular membranes, blue signals, the nucleus, and red signals, the nanoparticles: (A) 3T3 cells and (B) HeLa cells.
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platforms, targeted MLPs are a good example. Indeed, a wide
range of ligand-bearing MLPs (or liposomes) have been
described to date.9,25−30
In the present work, functionalized MLPs bearing RGD
moieties were used for the specific labeling of αVβ3-integrin-
expressing HeLa cells and for the unspecific labeling of 3T3
fibroblasts (which also present integrins on their surface but are
collagen receptors and not RGD receptors).31 The cell
interactions of the RGD-MLPs were compared to those of
RGD-lacking MLPs (with or without PEG).
We first prepared iron oxide nanoparticles stabilized with PEG,
which is currently considered to be the best antibiofouling agent
and described as GRAS (generally regarded as safe) by the U.S.
Food and Drug Administration. The ferrofluid was encapsulated
in bare liposomes and in liposomes with PEG attached covalently
to the lipid surface. Furthermore, a part of the PEGylated
liposomes was functionalized with cyclic peptide RGD to
generate RGD-MLPs. The average diameter of the obtained
MLPs was lower than 220 nm (≈the pore size of the membranes
used). The reduction of size in all types of the prepared
liposomes was due to the presence of CHOL because it produces
a condensation effect resulting from particular changes in the
phase behavior elicited by CHOL.32 Moreover, compared with
MLPs, PEG-MLPs and RGD-MLPs presented a significantly
lower diameter due to the insertion of PEG. PEG affects
compressibility and the packing of the lipid bilayer, with PEG-
DSPE concentrations higher than 8mol % decreasing the particle
size due to the appearance of PEG-DSPE-enrichedmicelles at the
expense of liposomes.33 Regarding the number of iron oxide
cores inside the liposomes, the theoretical value of 1−2 cores per
liposome is consistent with the inner volume of an average
liposome (with a diameter of 150 nm) and the hydrodynamic
radius of a nanoparticle of ferrofluid because the high
hydrophilicity of PEG involves a high level of hydration of the
polymer.
Historically, iron oxide nanoparticles have been considered
safe given the high levels of iron ions that can be tolerated (up to
4 mM). However, some groups have more recently shown that
exposure to iron oxide nanoparticles can lead to a wide variety of
toxic effects impacting the cell morphology, cytoskeleton,
proliferation, viability, and cellular homeostasis.34−37 Our results
showed that the MLPs used in this study were not toxic to 3T3
and HeLa cells, when using the NR assay (IC50 > 12 mM). This
value was lower for the MTT assays, which measure levels of
mitochondrial dehydrogenase enzymes (Figure S1, Supporting
Information). Our data indicated that bare liposomes and MLPs
were innocuous up to a lipid concentration of 10 mM after 24 h
of incubation (Table S1 and Figures S2 and S3). By contrast,
RGD-MLPs and PEG-MLPs exhibited an appreciable toxicity
that differed in its extent between the 3T3 and HeLa cells
(Figures S4 and S5). For instance, RGD-MLPs, at a lipid
concentration of 0.6 mM, reduced cell viability to 73.2 ± 5.6% in
3T3 cells and 81.4 ± 3.6% in HeLa cells (in the MTT assays). At
the same concentration, bare MLPs and bare liposomes gave cell
viabilities of ca. 100% in 3T3 and HeLa cells for both the NR and
MTT assays. As a control, there were no cytotoxic effects when
identical volumes of a nanoparticle-free buffer were used to
replace the medium, indicating that the reduction in cell viability
was not due to a limited nutrient supply.38 The toxic effects could
be attributed to any of the components present in the liposome
(e.g., the maleimide group or the cyclic peptide). Although a lack
of toxicity of liposomes bearing the maleimide group has been
shown previously,39 the toxicity of both RGD-MLPs and PEG-
MLPs could be due to the cyclic peptide promoting the toxicity
elicited by the maleimide group.
Figure 9.Confocal microscopy analysis of the intracellular distribution of PEG-MLPs after three times of incubation (2, 4, and 24 h). Green fluorescent
signals indicate the cellular membranes, blue signals, the nucleus, and red signals, the nanoparticles: (A) 3T3 cells and (B) HeLa cells.
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Our flow cytometry results were initially quite surprising.
MLPs, regardless of their composition, were internalized to a
greater extent than the nonmagnetic liposomes in both cell lines
(Table 1). For instance, the increase in the mean fluorescence
intensity produced by MLPs was more than twice (8.46 vs 3.83)
that obtained with bare liposomes in HeLa cells. Not less
surprising, PEGylated liposomes (with or without iron oxide
nanoparticles) produced the lowest values for cell binding.
Although all of the systems become aggregated as a consequence
of their interaction with the media components, the kinetics of
the aggregation is different, and for that reason, the MLPs are
probably taken up quicker than the functionalized samples.
Internalization of these nanoparticles was investigated by
confocal microscopy, and the results were wholly consistent
with those obtained with flow cytometry. Figures 7 and 8
demonstrate that time was a key factor in the internalization
process; the highest degree of internalization of MLPs in HeLa
cells was seen at 4 h of incubation, whereas the highest
internalization in 3T3 cells was observed at 24 h. After
internalization, nanoparticles are initially confined inside endo-
somes, which are submicrometric vesicles of the endocytic
pathway.40,41 Therefore, the red areas in Figure 7 show MLPs
that have been internalized into endosomal compartments.
RGD-MLPs were poorly internalized in 3T3 cells and not at all in
HeLa cells at any of the time points examined. These results
supported our flow cytometry data but are not in line with most
of the other studies on RGD.9,26,29,42,43 The absence of RGD-
MLP internalization could be because RGD-MLPs remain
primarily linked to the cell surface, with the repeated washes
performed before the microscopic experiments causing the
nanoparticles to detach from the cell surface. Previous studies
have demonstrated that nanoparticle internalization in HeLa
lines strongly depends on the nanoparticle coating charge,
nature, concentration, and incubation time.44,45 Thus, nano-
particles with low surface charge or negative charge are hardly
endocytosed by these cells, partly explaining the lack of
internalization of RGD-MLPs, which display a low surface
charge. By contrast, cationic nanoparticles were detected inside
the cells under all experimental conditions.
We observed greater internalization of MLPs than that of their
nonmagnetic counterparts, the reasons for which remain unclear.
The extremely low cellular uptake of RGD-MLPs (or RGD-
liposomes) in HeLa cells despite the specific targeting could be
explained by the presence of PEG. PEGylation has been, for
many years, used to avoid the interaction between any carrier and
the components of biological fluids. Although PEGylated carriers
are effectively delivered to tumor tissue via an EPR effect, the
cellular uptake efficiency of PEGylated carriers is known to be
low. This problem is recognized as the PEG dilemma.46−48 It has
been shown that PEGylation diminishes the absolute amount of
protein bound to the liposomes but does not impede the
formation of the protein layer surrounding the liposome (the
protein corona).49 To overcome this drawback and enhance the
cellular uptake efficiency of PEGylated carriers, ligands targeting
surface proteins on cancer cells have been attached to the tip of
PEG.50,51 The aim of our study was to facilitate and increase the
cellular uptake of nanoparticles by incorporating RGD. However,
as we have demonstrated, RGD-MLP internalization was almost
similar to the uptake of their PEGylated counterparts despite the
presence of the ligand. It is evident that these PEGylated systems,
with longer circulation time in the bloodstream, interact
inefficiently with cell membranes. In other words, when PEG is
attached to the liposomal surface, the designed active targeting is
masked. Therefore, it is necessary to find the best compromise
between an antiopsonization strategy and efficient cellular uptake
because an optimal balance between PEGylation and RGD
loading is required for targeting in vivo. In some cases, higher
RGD loading could be applied to increase cell binding (or
similarly, a reduction in PEGylation could be used to increase
binding), whereas in others, the use of ligand-targeted liposomes
without PEG or with a shorter-chain PEG could be a reasonable
strategy.52
■ CONCLUSIONS
The cellular uptake of MLPs is strongly related not only to the
surface grafting of the nanoparticle but also to the presence of
encapsulated iron nanoparticles. While PEGylation inhibits
internalization, the targeting RGD moiety does not favor
internalization, even in cells with RGD receptors. Furthermore,
bare MLPs are internalized more than the other types of MLPs,
regardless of the cell type. Therefore, the cellular uptake of
ligand-targeted MLPs is inhibited by PEG. To achieve cell
interaction and internalization of targeting nanoparticles, their
surfaces have to display ligands that exceed the length of the
polymer chain to prevent the protein corona impeding the
binding ability of the ligand. However, it seems more
straightforward to use two PEG chains of different lengths.53,54
The short PEG chains afford the steric stability of the
nanoparticles, whereas the longer ones help locating the ligand.
Consequently, the long arm facilitates the interaction with the
cellular receptor, whereas the short arm prevents the adsorption
of proteins on the particles’ surface. In this way, the ligands must
be attached at the tip of a PEG chain longer than the PEG chains
used to provide steric stabilization.
Experimental Procedures. Synthesis and Character-
ization of Magnetoliposomes. Iron oxide magnetic ferrofluid
was synthesized by coprecipitating two iron salts in the presence
of PEG with a molecular weight of 6000 Da, as described by
Garciá-Jimeno and Estelrich.55MLPs were prepared with DMPC
(P7930, Sigma-Aldrich, St. Louis, MO) and CHOL (C8667,
Sigma-Aldrich) at an 80:20 molar ratio. PEG-MLPs were made
with DMPC, CHOL, and DSPE-PEG2000 (880160P, Avanti
Polar Lipids, Alabaster, AL). RGD-MNPs were prepared with
DMPC, CHOL, and DSPE-PEG2000 (880160P, Avanti Polar
Lipids), as well as maleimide-PEG-DSPE (DSPE-PEG-MAL)
(880126P, Avanti Polar Lipids), and modified with RGD. The
cyclic RGD peptide (Arg-Gly-Asp-D-Phe-Cys, purity assayed by
HPLC to be >99%) was obtained from Caslo (Lyngby,
Denmark). Lipids used either for MNPs or for RGD-MNPs
were dried by evaporating at reduced pressure (Rotovapor R-
200, Buchi, Switzerland) at 40 °C. The obtained lipid films were
hydrated with a suspension of ferrofluid in water at an iron
concentration of 0.67 mg/mL (12 mM). Liposomes were
obtained by sequential extrusion through polycarbonate
membranes with pore sizes of 800 nm (3 times), 400 nm (3
times), and 200 nm (4 times) in an Extruder device (Avestin,
Ottawa, Canada). The nonencapsulated ferrofluid was separated
from MLPs by adding an equal volume of 320 mM NaCl. The
nonincorporated ferrofluid was precipitated by gentle centrifu-
gation at 2000 rpm for 5 min. The supernatant contained the
purified MLPs. RGD-MLPs were prepared similarly: DMPC/
CHOL/DSPE-PEG-MAL were mixed at molar ratios of 80:20:3
and hydrated with a suspension of the ferrofluid. Once the
liposomes were extruded and purified, RGD dissolved in water
was coupled to the corresponding liposomal surface by a
chemical reaction at room temperature overnight between the
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maleimide groups at the distal end of DSPE-PEG-MAL on the
liposomes and the sulfhydryl group of cysteine in the cyclic RGD,
at a molar ratio of 1:10 (RGD/maleimide).27 To determine the
cellular uptake of liposomes by confocal microscopy and flow
cytometry, liposomes were labeled with fluorescence probe 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
Rho sulfonyl) (ammonium salt) (810157C, Avanti Polar Lipids).
The probe in chloroform/methanol (2:1, v/v) was added to the
organic lipid mixture and proceeded as indicated above. The
microscopic images were acquired in probe-corrected Jeol ARM-
200 equipped with a field emission gun electron source operating
at 200 kV. Z-contrast images were collected using an HAADF
detector, in scanning transmission mode (STEM). Particle size
distribution and ζ-potential were determined by PCS using
Zetasizer Nano (Malvern, U.K.). The magnetic properties of the
magnetic particles were evaluated using a superconducting
quantum interference device magnetometer (Quantum design
MPMS XL). Phospholipid and iron concentrations in the
liposomal samples were determined by the Steward56 and
Kiwada57 methods, respectively.
Cell Culture. The 3T3 (murine Swiss albino embryo
fibroblasts) and HeLa (human epithelial cervical cancer) cell
lines were obtained from Eucellbank (Universitat de Barcelona).
Cells were routinely cultured in 75 cm2 culture flasks and grown
in Dulbecco’s modified Eagle’s medium (DMEM) (56499C,
Sigma-Aldrich) supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS) (10082, Invitrogen), 4.5 g/L glucose, 2
mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin (“complete medium”) at 37 °C and 5% CO2.
After cells became ∼80% confluent, they were removed from the
culture flask by trypsinization (0.25% trypsin + 0.1% EDTA) and
suspended in complete medium.
Cell Viability. Quantitative viability of the 3T3 and HeLa
cells in the presence of MNPs was assessed using the MTT and
NR assays, as described elsewhere.58 The first measures
metabolic activity in the mitochondria of viable cells,59 whereas
NR accumulates in the lysosomes of viable undamaged cells.60
3T3 cells (1 × 105 cells mL−1) and HeLa cells (5 × 104 cells
mL−1) were seeded onto a 96-well plate in 100 μL of complete
medium. After subculturing for 24 h at 37 °C and 5% CO2, the
medium was replaced with 100 μL of fresh medium
supplemented with 5% FCS containing the MLPs in the
phospholipid concentration range of 0.08−10 mM (with an
iron content ranging from 0.03 to 4 mM). The control group
consisted of cells in DMEM supplemented with 5% fetal bovine
serum without MLPs. Experiments were carried out in triplicate.
After exposure for 24 h toMLPs, PEG-MLPs, or RGD-MLPs, the
nanoparticles were removed. Subsequently, 100 μL of MTT
solution (1 mg mL−1), previously diluted with DMEM without
FCS or phenol red, was added to each well at a final
concentration of 0.5 mg mL−1. After 3 h of incubation at 37
°C, the MTT solution was removed by aspiration and 100 μL of
dimethyl sulfoxide was added to each well to dissolve the purple
formazan crystals. Plates were then placed in a microtiter plate
shaker and gently shaken for 10 min at room temperature to
achieve complete dissolution. Finally, the absorbance of each well
was measured at 550 nm using a Bio-Rad 550 microplate reader.
Cell viability was expressed as the percentages of viable cells
compared with the survival rates of the control group (untreated
cells showed 100% viability). In the NR assay, after incubating
cells with MLPs for 24 h, an additional incubation for 3 h was
performed with an NR solution (50 μgmL−1) in DMEMwithout
FCS or phenol red. Cells were then washed with PBS, followed
by the addition of 100 μL of a solution containing 50% absolute
ethanol and 1% acetic acid in distilled water to extract NR. Plates
were gently shaken for 10 min to ensure complete dissolution,
and the absorbance of the extracted solution was read at 550 nm
as above. The effect of each type of MLP was calculated as the
percentage of NR uptake by lysosomes compared to that in
control (untreated cells). Viability was determined as in the
MTT assay.
Flow Cytometry. The interaction between the MLPs and
3T3 or HeLa cells was determined by flow cytometry. 3T3 cells
(1 × 105 cells mL−1) and HeLa cells (5 × 104 cells mL−1) were
seeded onto 24-well plates in 500 μL of complete medium. The
cells were then incubated for 24 h at 37 °C under 5% CO2. The
medium was replaced with 500 μL of fresh DMEM
supplemented with 5% FCS containing the MLPs at a
phospholipid concentration of 0.6 mM. After 4 h of incubation,
the MLPs were removed and the cells were washed three times
with PBS and harvested with trypsin/EDTA (100 μL) for 3−5
min at 37 °Cunder 5%CO2. Cells were resuspended in 500 μL of
fresh DMEM supplemented with 10% FCS and analyzed by flow
cytometry using a FACSAria I SORP sorter (Becton Dickinson,
San Jose, CA). Excitation of the sample was achieved using a blue
laser (488 nm) for forward scatter (FS). A green laser (561 nm)
was used to excite Rho present in the bilayer of MLPs, and the
red emission (575 ± 12.5 nm) was collected in log modes. Cells
were gated by sideward scatter (SS) versus forward scatter (FS)
and selected according to their FS/SS signal. Fluorescence
measurements were undertaken according to this gate. A
minimum of 10 000 (3T3 cells) or 3900 (HeLa cells) gated
events were collected and analyzed. Dot blot analysis was
performed using the software supplied by the manufacturer. All
experiments were repeated twice, but results are presented from a
single experiment.
Confocal Microscopy. Cell adhesion and MLP localization
in both cell lines were assessed by confocal microscopy using a
Leica TCS−SP2 laser scanning confocal microscope (Heidel-
berg, Germany). The cell membrane was stained with the cell-
membrane-impermeable dye Alexa Fluor 488-conjugated WGA
in ice-cold PBS for 10 min. The nucleus was stained using
membrane-permeable dye Hoechst 33342 (L7528, Invitrogen).
Cells were washed three times with ice-cold PBS, and the
coverslips with the cells were mounted on glass slides onto
ProLong Gold antifade reagent. For every sample, 15-z scans
(horizontal cross section of a cell at a particular z height) were
taken at a 0.25 μm z-step height to cover the entire height of the
cell. On the confocal images, liposomes are shown in red, the cell
membrane, in green, and the nucleus, in blue.
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■ ABBREVIATIONS
CHOL, cholesterol; DMPC, 1,2-dimyristoyl-sn-glycero-3-phos-
phocholine; DSPE-PEG, 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[maleimide (polyethylene glycol)-2000] (am-
monium salt) (DSPE-Mal-PEG-2000); EPR, enhanced perme-
ability and retention; FCS, fetal calf serum; FS, forward scatter;
IC50, half-maximal inhibitory concentration; HAADF, high angle
annular dark field; MLPs, magnetoliposomes; MNPs, magnetic
nanoparticles; MTT, 3-4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromide; NR, neutral red; PCS, photon correlation
spectroscopy; PEG, poly(ethylene glycol); PEG, 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (ammonium salt); RGDc, cyclic arginine-glycine-
aspartate peptide; Rho, rhodamine B; SS, sideward scatter;
WGA, wheat germ agglutinin
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(9) Hölig, P.; Bach, M.; Völkel, T.; Nahde, T.; Hoffmann, S.; Müller,
R.; Kontermann, R. E. Novel RGD lipopeptides for the targeting of
liposomes to integrin-expressing endothelial and melanoma cells.
Protein Eng., Des. Sel. 2004, 17, 433−441.
(10) Pierschbacher, M. D.; Ruoslahti, E. Influence of stereochemistry
of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion.
J. Biol. Chem. 1987, 262, 17294−17298.
(11) Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGD-
based strategies for selective delivery of therapeutics and imaging agents
to the tumour vasculature. Drug Resist. Updates 2005, 8, 381−402.
(12) Bogdanowich-Knipp, S. J.; Chakrabarti, S.; Williams, T. D.;
Dillman, R. K.; Siahaan, T. J. Solution stability of linear vs. cyclic RGD
peptides. J. Pept. Res. 1999, 53, 530−541.
(13) Zitzmann, S.; Ehemann, V.; Schwab, M. Arginine-glycine-aspartic
acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in
vivo. Cancer Res. 2002, 62, 5139−5143.
(14) Maurer, N.; Fenske, D. B.; Cullis, P. R. Developments in
liposomal drug delivery systems. Expert. Opin. BIol. Ther. 2001, 1, 923−
947.
(15) Lasic, D. D. Recent developments in medical applications of
liposomes: sterically stabilized liposomes in cancer therapy and gene
delivery in vivo. J. Controlled Release 1997, 48, 203−222.
(16) Maeda, H.; Wu, J.; Matsumura, Y.; Hori, K.; et al. Tumor vascular
permeability and the EPR effect in macromolecular therapeutics: A
review. J. Controlled Release 2000, 65, 271−284.
(17) Lasic, D. D. Doxorubicin in sterically stabilized liposomes.Nature
1996, 380, 561−562.
(18) Torchilin, V. Tumor delivery of macromolecular drugs based on
the EPR effect. Adv. Drug Delivery Rev. 2011, 63, 131−135.
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